Dataset Information

Empirical validation of patient versus population preferences in calculating QALYs.

ABSTRACT: A fundamental assumption of the quality-adjusted life year model is mutual utility independence between life years and health status. However, this assumption may not hold for severe health states: living in a severe health state may cause disutility beyond a so-called maximal endurable time (MET). It is unknown, however, whether persons without experience of a disease, who are often used in health state valuation exercises, account for MET. Using data from 159 respondents from two convenience samples in Germany who were presented a health state description of depression, this study shows that persons without experience of depression had a lower rate of MET than persons with a history of depression. Furthermore, they had more preference reversals in case of MET, thus violating a fundamental principle of rational choice theory. While these findings suggest that severe health states should be assessed by patients rather than the community, confirmation in additional studies outside Germany and based on other health-state valuation techniques and diseases is recommended.

SUBMITTER: Weyler EJ

PROVIDER: S-EPMC3207192 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Empirical validation of patient versus population preferences in calculating QALYs.

Weyler Eva-Julia EJ Gandjour Afschin A

Health services research 20110421 5

A fundamental assumption of the quality-adjusted life year model is mutual utility independence between life years and health status. However, this assumption may not hold for severe health states: living in a severe health state may cause disutility beyond a so-called maximal endurable time (MET). It is unknown, however, whether persons without experience of a disease, who are often used in health state valuation exercises, account for MET. Using data from 159 respondents from two convenience s ...[more]

PMID: 21517837

Similar Datasets

Project description:BackgroundThe emergence of proprotein convertase subtilisin/kexin type 9 inhibitors offered dyslipidemia patients an alternative to statins for lipid-lowering treatment. Understanding patient and physician preferences for lipid-lowering drugs may promote shared decision-making and improve treatment outcomes.MethodsThis study utilized an online discrete choice experiment (DCE) to assess the relative importance (RI) of six attributes related to lipid-lowering drugs, including frequency of administration, mode of administration, reduction of low-density lipoprotein cholesterol (LDL-C) level, risk of myopathy, risk of liver damage, and out-of-pocket monthly cost. Respondents were recruited from dyslipidemia patients and cardiovascular physicians in China. A mixed logit model and latent class analysis were employed to estimate the preference coefficient, marginal willingness to pay (mWTP), and RI of attributes. Ethical approval has been obtained for this study.ResultsA total of 708 patients and 507 physicians participated in the survey. Patients prioritized the 'risk of liver damage' (RI = 23.6%) with 'mode of administration' (RI = 19.2%) and 'frequency of administration' (RI = 18.8%) following closely. Contrarily, physicians prioritized the 'reduction of LDL-C level' (RI = 33.5%), followed by 'risk of liver damage' (RI = 26.0%) and 'risk of myopathy' (RI = 16.1%). Patients placed a higher value on 'frequency of administration' (p < .001) and 'mode of administration' (p < .001) compared to physicians, while physicians valued 'reduction of LDL-C level' (p < .001) and 'risk of myopathy' (p = .012) more than patients. Physicians exhibited higher mWTP than patients for all attributes except frequency and mode of administration. The LCA revealed three distinct patient classes: focus on oral administration, focus on hepatic safety and frequency and focus on hepatic safety and cost. Likewise, three physician classes were identified: frequency-insensitive, efficacy-focused and safety-focused.ConclusionsThe preferences for lipid-lowering drug therapy differed between patients and physicians in China. Physicians should take into account patients' preferences and provide personalized treatment when they formulate lipid-lowering treatment plans.Patient or public contributionPatients participated in the questionnaire design process. They engaged in a focus group discussion to determine attributes and levels and also participated in a pilot survey to assess the comprehensibility of the questionnaires. Additionally, patients were involved in the DCE survey to express their preferences. The findings of patient preference for lipid-lowering drug therapy will promote shared decision-making and optimize the treatment regimen.

Project description:ObjectiveThe patent expiry of a number of biological medicines and the advent of biosimilars raised the expectations of healthcare commissioners that biosimilars would reduce the high cost of these medicines and produce potential savings to the NHS. We aimed to examine the prescribing pattern of different growth hormone preparations (ready to use and reconstitution requiring) in primary and secondary care in England to determine relative rates of decrease or increase and identify the possible factors influencing prescribing following the introduction of biosimilar growth hormone in 2008.DesignLongitudinal observational study.Setting and data sourcesPrimary care prescribing cost and volume data was derived from the NHS business services authority website, and for secondary care from the DEFINE database, between April 2011 and December 2015.OutcomesQuarterly prescribing analysis to examine trends and measure the relationship between usage and price.ResultsExpenditure and usage of growth hormone in primary care decreased by 17.91% and 7.29%, respectively, whereas expenditure and usage in secondary care increased by 68.41% and 100%, respectively, between April 2011 and December 2015. The usage of reconstitution requiring products significantly declined in primary care (R²=0.9292) and slightly increased in use in secondary care (R²=0.139). In contrast, the usage of ready-to-use products significantly increased in use in primary (R²=0.7526) and secondary care (R²=0.9633), respectively. Weak or no correlation existed between the usage and price of growth hormone preparations in primary and secondary care.ConclusionsThe price of growth hormone products was not the key factor influencing the prescribing of the biological medicines. The main driver for specific product selection was the ease of use and the number of steps in dose preparation. Prescribers appear to be taking into account patient preferences rather than cost in their prescribing decisions.

Dataset Information

Empirical validation of patient versus population preferences in calculating QALYs.

Publications

Empirical validation of patient versus population preferences in calculating QALYs.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets